Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Surotomycin"'
Publikováno v:
BMC Pharmacology and Toxicology, Vol 18, Iss 1, Pp 1-8 (2017)
Abstract Background Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models. Methods S
Externí odkaz:
https://doaj.org/article/0cf3e92ee1bc41ab93402107e6deea2a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Fatima Rawish, Desai Madhav, Aziz Muhammad, Thoguluva Chandrasekar Viveksandeep, Sharma Prateek, Jackson Mollie, Eid Albert
Publikováno v:
Current Clinical Pharmacology. 14:166-174
Background: Current guidelines recommend the use of vancomycin for the initial treatment of moderate to severe Clostridioides difficile Infection (CDI). Surotomycin, a novel antibiotic, has been utilized for the management of CDI with variable result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fce951467da0aa951ca1813397559327
https://doi.org/10.2174/1574884714666190328162637
https://doi.org/10.2174/1574884714666190328162637
Autor:
Kevin Patrick Field, Amy E. Bryant, Michael J. Aldape, Dennis L. Stevens, Savannah Nicole Rice
Publikováno v:
Journal of Medical Microbiology. 67:1689-1697
PURPOSE: Clostridium difficile is an anaerobic spore-forming bacterial pathogen that causes a spectrum of illness severity ranging from mild diarrhoea to severe life-threatening pseudomembranous colitis. C. difficile infection (CDI) is antibiotic-ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272bab5f4ee5b037b839303fd5073370
https://doi.org/10.1099/jmm.0.000852
https://doi.org/10.1099/jmm.0.000852
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Antibiotics are lifesaving therapeutic drugs that have been used by human for decades. They are used both in the fight against bacterial pathogens for both human and for animal feeding. However, of recent, their effects on the gut microbial compositi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______9436::a209761b7fef37f88e6a2b074dbdd1f8
https://hdl.handle.net/11454/77831
https://hdl.handle.net/11454/77831
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
Scientific Reports
Scientific Reports
Clostridium difficile infections (CDIs) are a growing health concern worldwide. The recalcitrance of C. difficile spores to currently available treatments and concomitant virulence of vegetative cells has made it imperative to develop newer modalitie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c712057d60856b8bd91e56010e850c
https://doi.org/10.1038/s41598-020-62496-9
https://doi.org/10.1038/s41598-020-62496-9
Publikováno v:
European Journal of Clinical Microbiology and Infectious Diseases
European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38 (2), pp.209--231. ⟨10.1007/s10096-018-3419-z⟩
European Journal of Clinical Microbiology & Infectious Diseases
European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 (2), pp.209--231. ⟨10.1007/s10096-018-3419-z⟩
European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38 (2), pp.209--231. ⟨10.1007/s10096-018-3419-z⟩
European Journal of Clinical Microbiology & Infectious Diseases
European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 (2), pp.209--231. ⟨10.1007/s10096-018-3419-z⟩
WOS:000457394800002; Clostridium difficile infections (CDI) dramatically increased during the last decade and cause a major public health problem. Current treatments are limited by the high disease recurrence rate, severity of clinical forms, disrupt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e3be6768831663282a542ee1d6ab10c
https://doi.org/10.1007/s10096-018-3419-z
https://doi.org/10.1007/s10096-018-3419-z
Autor:
Christoph Lübbert, A. von Braun
Publikováno v:
Der Internist. 59:505-513
The incidence of clostridium difficile infections (CDI) remains on a high level globally. In Germany, the number of severe or even lethal cases continues to increase. The main risk factor for the development of CDI is exposure to broad spectrum antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bac789f0cbffa8a3361a66cba3b6c99
https://doi.org/10.1007/s00108-018-0401-x
https://doi.org/10.1007/s00108-018-0401-x
Autor:
Lifen Ling, Christopher R. Polage, Zhong Peng, Charles W. Stratton, Yi-Wei Tang, Bin Wu, Chunhui Li
Publikováno v:
Emerging Microbes & Infections
Clostridium difficile is a leading cause of antibiotic-associated diarrhea worldwide. The diagnosis of C. difficile infection (CDI) requires both clinical manifestations and a positive laboratory test for C. difficile and/or its toxins. While antibio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf07ce10121ec10306e725acce2418a
https://doi.org/10.1038/s41426-017-0019-4
https://doi.org/10.1038/s41426-017-0019-4